Fig. 1

circATP9A was upregulated in NSCLC tissues and associated with poor clinical features. Notes: A The cluster heat maps showed the differentially expressed circRNAs in NSCLC tissues and paired NATs from GSE112214; B The cluster heat maps showed the differentially expressed circRNAs in NSCLC tissues and paired NATs from GSE158695; C The overlapping analysis of upregulated circRNAs in GSE112214 and GSE158695; D Schematic illustration showed the circularization of ATP9A exons 2 and 3 to form circATP9A. The back-splicing junction of circATP9A was verified by RT-PCR and Sanger sequencing; E circATP9A expression in A549 cells verified by RT-PCR. Agarose gel electrophoresis showed that divergent primers amplified circATP9A in cDNA but not gDNA; F Representative ISH images from scramble probe (red: negative control), U6 probe (blue: positive control) and circATP9A probe in NSCLC tissues and paired NATs; G The expression level of circATP9A in NSCLC tissues and paired normal adjacent tissues (NATs) by qRT-PCR; H The expression level of circATP9A in NSCLC patients stratified by stage; I, J qRT-PCR detected the expression of circATP9A and linATP9A in NSCLC cell lines with or without RNase R or actinomycin D treatment; K FISH assay identifying the subcellular location of circATP9A in the A549 and H1299 cell lines